1. Howqua J, Mackay IR. LE cells in lymphoma. Blood 1963;22:191-198.

2. Whitehouse JMA, Holborow EJ. Smooth muscle antibody in malignant disease. Br Med J 1971 ;4:511.

3. Burnham TK. Antinuclear antibodies in patients with malignancies. Lancet 1972;2:436-437.

4. Hamilton-Fairley G. Autoantibodies in malignant disease. Br J Haematol 1972;23(suppl):231.

5. Ablin RJ. Malignancy associated with antinuclear antibodies. Lancet 1972;2:253-254.

6. Steiner M, Klein E, Klein G. Antinuclear reactivity of sera in patients with leukemia and other neoplastic diseases. Clin Immunol Immunopathol 1975;4:374— 381.

7. Hodson ME, Turner-Warwick M. Autoantibodies in patients with bronchial carcinoma. Thorax 1975;30: 367-370.

8. Fernández-Madrid F, Mattioli M. Antinuclear antibodies (ANA): immunological and clinical significance. Semin Arthrit Rheumatol 1976;6:83-124.

9. Lamelin JR, De-The G, Revillard JP, Gabbiani G. Autoantibodies, cold lymphocytotoxins, antiactin antibodies and antinuclear factors in nasopharyngeal carcinoma patients. IARC Sci Pub 1978;20: 523-536.

10. Osman J, Regan RJ, Dathan JR. Bilateral renal carcinoma with metastases in the gall bladder and associated with a strongly positive ANA. Br J Urol 1978;50:121.

11. Bentwich Z, Talpaz M, Schechter D. Antinuclear Antibodies, "ANA" in the sera of carcinoma patients: increased incidence with dissemination of the dis ease. Proc Am Assoc Cancer Res/Am Soc Clin Oncol 1979;20:14.

12. Marcus RM, Grayzel Al. A Lupus antibody syndrome associated with hypernephroma. Arthrit Rheumatol 1979;22:1396-1298.

13. Salem NB. Lupus antibody syndrome with intestinal lymphoma. Arthrit Rheumatol 1980;23:613.

14. McCarty GA. Autoimmunity and malignancy. Med Clin North Am 1985;69:599-615.

15. Chen Y-M, Hu C-P, Chu MH, Tsai YT, Lee SD, Chang, C. Nuclear antigens reacted with sera and ascitis of hepatocellular carcinoma patients. Hepatology 1988;8:547-552.

16. Buddle-Steffen, C, Anderson, NE, Rosenblum, MK, Posner, JB. Expression of an antigen in small cell lung carcinoma lines detected by antibodies from patients with paraneoplastic dorsal root ganglionopathy. Cancer Res 1988;48:430^134.

17. Freundlich B, Makover D, Maul GG. A novel antinuclear antibody associated with a lupus-like paraneoplastic syndrome. Ann IntMed 1988;109:295-297.

18. Takimoto T, Ishikawa S, Masuda D, Tamaka D, Yoshizaki T, Umeda R. Antinuclear antibodies in the sera of patients with nasopharyngeal carcinoma. Am J Otolaryngol 1989;10:39-403.

19. Imai H, Ochs RI, Kiyosawa K, Furuta S, Nakamura RM, Tan EM. Am J Pathol 1992;140:859-870.

20. Smith P, Rice M, Ricci N, Toogood I, Robertson D. A case of Burkitt's lymphoma presenting with digital ischemia. Acta Paediatrica 1993;82:217-219.

21. Imai H, Nakano Y, Kiyosawa K, Tan EM. Increasing titers and changing specificities of antinuclear antibodies in hepatocellular carcinoma. Cancer 1993; 71:267-235.

22. Doutre MS, Beylot J, Beylot C, Abs L, Lacoste D. Systemic lupus erythematosus and Hodgkins' disease. Int J Dermatol 1994;33:436-437.

23. Burek GL, Rose NR. Autoantibodies In: RB Collins, HK Bhan, RT McCluskey, eds., Diagnostic Im-munopathology, 2nd edn., RB Clovin, AK Bhan, RT McCluskey, eds. New York: Raven Press, 1995;207-230.

24. Tan EM. Antinuclear antibodies. Diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989;44:93-151.

25. Tan EM. Antibody markers in systemic autoimmunity. In: Brandt KD, ed., Diagnostic Studies in Rheumatology. New Jersey: Ciba Geigy Summit, 1992.

26. Reichlin M. Autoantibodies to the RNP particles. Clin Exp Immunol 1995; 99:7-9.

27. Muro YC, Chan IE, Landberg G, Tan EM. A cell-cycle nuclear autoantigen containing WD-40 motifs expressed mainly in S and G2 phase cells. Biochem Biophys Res Commun 1995;207:1029-1037.

28. Sahin UÖ, Tureci H, Schmitt B, Cochlovius T, Johannes R, Schmitts F, Stenner G, Luo I, Schobert I and Pfreundschuh M, Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sei USA 1995;92:11810-11813.

29. Ttireci, Shain UÖ, Pfreundschuh M. Serological analysis of human tumor antigens: molecular definition and implications. Mol Med Today 1997;3:342-349.

30. Sahin UÖ, Ttireci, Pfreundschuh M. 97. Serological analysis of human tumor antigens. Curr Opin Immunol 1997;9:709-716.

31. Jäger E, Chen Y-T, Drijfout JW, Karback J, Ring-hoffer M, Jäger D, Arand M, Wada H, Noguchi Y, Stocken E, et al. Simultaneous humoral and cellular immune response against cancer-tests antigen NY-ESO-1: definition of HLA-A2 binding peptide epitopes. J Exp Med 1998;187:265-270.

32. Old, LJ, Chen, Y-T. New paths in human cancer serology. J Exp Med 1998;187:1163-1167.

33. Boon T, Old LJ. Cancer tumor antigens. Curr OP Immunol 1997;5:681-683.

34. Wolfel TM, Hauer et al. A pl6INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281-1284.

35. Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, Apelle E, Rosenberg SA. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996; 183(3): 1185-1192.

36. Mandruzzato S, Brasseur F, Andry G, Boon T, van der Brüggen P. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med 1997;186:785-793.

37. Winter SF, Minna JD, Johnson BE, Takahashi T, Gaz-dar AF, Carbone DP. Development of antibodies to p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992;52:4168-4174.

38. Ralhan R, Nath N, Agarwal S, Mathur M, Wasylyk B, Shukla NK. Circulating p53 Antibodies as early markers of oral cancer: correlation with p53 alterations. Clinical Cancer Research 1998;4:2147-2152.

39. Scanlan MJ, Chen Y-T, Williamson B, Gure AO, Stockert E, Gordan JD, Sahin U, Pfreundschuh M, Old LJ. Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer 1998;76:652-8.

40. Gure AO, Altorki NK, Stockert E, Scanlan MJ, Old LJ, Chen Y-T. Human lung cancer antigens recognized by autologous antibodies: definition of a novel cDNA derived from the tumor supressor gene locus on chromosome 3p21.3. Cancer Res 1998;58:1034-1041.

41. Erdile LF, Wold MS, Kelly TJ. The primary structure of the 32-kDa subunit of replication protein A. J Biol Chem 1990;265:3177-3182.

42. Fernández-Madrid F, Granda JL, Gimothy P, Van-deVord P, Kraut M, Yang X Tomkiel JE. Autoantibodies to subunits of replication protein A (RPA) in sera of patients with malignancies (abstract) Cancer Detection and Prevention 1998;22:5186.

43. García-Lozano R, González-Escribano F, Sánchez-Román J, Wichmann I, Núñez-Roldan A. Presence of antibodies to different subunits of replication protein A in autoimmune sera. Proc Natl Acad Sei USA 1995;92:5116-5120.

44. Fry WA, Menck HR, Winchester DP. The National Cancer Data Base report on lung cancer. Cancer 1996;77:1947-1955.

45. Petruzzelli S, Travanti LM, Celi A, Guintini C. Detection of n-methyl-deoxyguanosine adducts in human pulmonary alveolar cells. Am J Resp Cell Mol Biol 1996;15:216-223.

46. Hecht SS. Recent studies on mechanism of bioactiva-tion and detoxification of 4-methylnitrosamine)-l-(3-pyridyl) -1-butanone (NNK), a tobacco-specific lung carcinogen. Crit Rev Toxicol 1996;26:163-181.

47. Rubin E Farber J. The Respiratory System. Pathology, 2nd edn. Philadelphia, PA: J.B. Lippincott, 1994;557-617.

48. Sturgis EM. Miller RH. Second primary malignancies in the head and neck cancer patient. Ann Otol Rhinol and Laryngol 1995;104:946-954.

49. Brenner SE, Lippman SM, Hong WK. Retinoid chemoprevention of second primary tumors. Semin Hematol 1994;31(4)(supp 5):26-30.

50. Luchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 1998;50(3):652-657.

51. Graus F, Dalmau J, Rene R, Tora M, Malats N, Verschuuren JJ, Cardenal F, Viflolas N, Garcia del Muro J, Vadell C, Mason WP, Rosell R, Posner JB, Real FX. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 1997; 15(8):2866—2872.

52. Brieman L, Friedman JH, Olshen RA, Stone CJ. Classification of Regression Trees. Belmont, CA: Wadsworth, 1984.

53. Clark LA, Pregibon D. Tree-based models. In: Chambers JM, Haste TJ, eds., Statistical Association. 1958;53:457-481.

54. Fernández-Madrid F, Granda JL, VandeVord PJ, Kar-vonen RL, Kraut MJ, Yang X, Tomkiel JE. Anti-

nuclear antibodies in lung cancer (abstract). Cancer Detection and Prevention 1998;22:S185.

55. Fernández-Madrid F, Karvonen RL, Kraut MJ, Czelusniak B, Ager J. Autoimmunity to collagen in human lung cancer. Cancer Res 1996;56:121-126.

56. Aho K, Koskola P, Makitalo R, Heliovaara M, Palosuo T. Antinuclear antibodies heralding the onset of Systemic Lupus Erythematosus. J Rheumatol 1992;19:1377-1379.

57. Swissa M, Amital-Teplizki H., Haim N, Cohen Y, Shoenfeld Y. Autoantibodies in neoplasia. An unresolved enigma [see comments]. Cancer 1990;65:2554-2558.

58. Frenkel K, Karkoszka J, Kato J, Powell J, Pero R. Systemic biomarkers of cancer risk. Cancer Detection and Prevention 1996;20:234.

59. Houghton AN. Cancer antigens: Immune recognition of self and altered self. J Exp Med 180; 1:1-4.

60. Wold MS. Kelly TJ. Purification and characterization of replication protein A, a cellular protein required for in vitro replication of Simian virus 40 DNA. Proc Natl Acad Sci USA. 1988;85:2523-2527.

61. Erdile LF, Heyer WD, Kolodner R, Kelly, TJ. Characterization of a cDNA encoding the 70-kDa single stranded DNA-binding subunit of human replication protein A and the role of the protein in DNA replication. Biol Chem 1991;266:1290-1298.

62. Umbricht CB, Erdile LF, Jabs EW, Kelly TJ. Cloning overexpression and genomic mapping of the 14 kDa subunit of human replication protein A. J Biol Chem 1993;268:6131-6138.

63. Tang CM, Tomkinson AE, Lane WS, Wold MS, Seto E. Replication protein A is a component of a complex that binds the human metallothionein II a gene transcription start site. J Biol Chem 1996;271:21637-21644.

64. Kin C, Paulus BF, Wold MS. Interactions of human replication protein A with oligonucleotides. Biochemistry. 1994;33:14197-14206.

65. Li L, Lu X, Peterson CA, Legerski RJ. An interaction between the DNA repair factor XPA and replication protein A appears essential for nucleotide excision repair. Mol Cell Biol 1995;15:5396-53402.

66. Lee SH, Kim DK, Drissi R. Human xeroderma pigmentosum group A protein interacts with human replication protein A and inhibits DNA replication. J Biol Chem 1995;270:21800-21805.

67. Matsuda T, Saijo M, Kuraoka I, Kobuyashi T, Nakatsu Y, Nagai A, Enjoji T, Masutani C, Sugasawa K, Hanaoka F et al. DNA repair protein XPA binds replication protein (RPA). J Biol Chem 1995;27:4152-4157.

68. Miller SD, Moses K, Jayaramin L, Prives C. Complex formation between p53 and replication protein A inhibits the sequence specific DNA binding of p53 and is regulated by single stranded DNA. Mol Cell Biol 1997;17: 2194-2211.

© 2000 Elsevier Science B. V. All rights reserved.

Cancer and Autoimmunity

Y. Shoenfeld and M. E. Gershwin, editors

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment